

185pp

December 20, 2001

FYI - 0102 - 01378

RECEIVED
CPPT CBIC

2002 JAN -7 AM 11:03

3M

Document Processing Center (7407)
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
401 M Street SW
Washington, D.C. 20460

MR 53270

Attention: For Your Information Docket - Docket No. AR-226Re: Information on Perfluorooctane
Sulfonates and Related Compounds

Dear Sir or Madam:

This continues 3M's voluntary submissions of data on perfluorooctane sulfonates and related compounds, as part of our ongoing dialogue with EPA regarding fluorochemicals. We are enclosing two studies as more fully described below.

Enclosed you will find the following:

1. Final Report, A Cross-sectional Analysis of Serum Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) in Relation to Clinical Chemistry, Thyroid Hormone, Hematology and Urinalysis Results from Male and Female Employee Participants of the 2000 Antwerp and Decatur Fluorochemical Medical Surveillance Program, October 11, 2001.
2. Final Report, A Longitudinal Analysis of Serum Perfluorooctanesulfonate (PFOS) and Perfluorooctanoate (PFOA) Levels in Relation to Lipid and Hepatic Clinical Chemistry Test Results from Male Employee Participants of the 1994/95, 1997 and 2000 Fluorochemical Medical Surveillance Program, October 11, 2001.

We will continue to provide information on a regular basis as it becomes available. We look forward to our continuing dialogue with the agency. Please feel free to contact me with any questions.

Very truly yours,

Michael A. Santoro
Michael A. Santoro
Director of Environmental, Health
Safety and Regulatory Affairs
Specialty Materials Markets
3M
Building 236-1B-10
St. Paul, MN 55144



FYI-00-001378

ORIGINAL

0000001

CONTAIN NO CBI



85020000008

RECEIVED
CPPT CBIC
2002 JAN 10 AM 8:37